This article is more than 5 years old. Information may no longer be current.
Low-dose aspirin decreases risk of complications for patients with GCA
Click Here to Manage Email Alerts
Both the rate of visual loss and cerebrovascular accidents in patients with giant cell arteritis can be decreased with low-dose aspirin therapy, according to a study.
Gideon Nesher and colleagues at the Shaare-Zedek Medical Center in Jerusalem retrospectively reviewed the charts of 175 patients in whom giant cell arteritis (GCA) was diagnosed. At the time of diagnosis, 36 patients (21%) had been receiving low-dose aspirin (100 mg/day). Ischemic heart disease was the diagnosis in all 36 patients. No significant differences existed between the aspirin-treated and non-aspirin-treated groups. At presentation, cranial ischemic complications were diagnosed in 43 patients; 30 had acute visual loss; 11 had cerebrovascular accidents and both conditions existed in two patients simultaneously.
Three of the aspirin-treated patients (8%) presented with cranial ischemic complications, compared with 40 (29%) of the non-aspirin-treated patients. Likewise, cranial ishcemic complications developed in only 3% of the aspirin-treated patients compared with 13% of the patients treated with steroid therapy.
The study is published in the April issue of Arthritis & Rheumatism.